Prevail InfoWorks’ Post

Glaucoma, often called the "silent thief of sight," presents a significant challenge in ophthalmology. Despite progress in treatment, several unmet needs persist, hindering effective management and vision preservation. Through early detection, personalized approaches, exploration of new therapeutic targets, surgical advancements, patient education, and collaborative care models, we can address these challenges and enhance outcomes in glaucoma management. It's crucial to unite efforts and innovate solutions to protect the precious gift of sight for millions affected by this insidious disease. Glaucoma often goes undetected in many patients due to various factors. According to DelveInsight Business Research LLP's estimates, of the 16 million prevalent cases in 2022 across the 7MM, only 7 million received a formal diagnosis. Prominent players such as NICOX OPHTHALMICS INC, Sun Pharma Advanced Research Company Ltd., Visiox Pharmaceuticals, and others are working proactively in the Glaucoma market. Explore more about the treatment options in the Glaucoma market @ https://lnkd.in/gQh2n8x4 #glaucoma #glaucomamarket #glaucomatreatmentmarket #glaucomatreatment #treatmentoptions #ophthalmology

Opthea announced the publication of a scientific review in the peer-reviewed journal Ophthalmology and Therapy. The publication, Vascular Endothelial Growth Factor (VEGF) C and D Signaling Pathways as Potential Targets for the Treatment of neovascular (wet) AMD supports the scientific rationale for sozinibercept (OPT-302) as a potential treatment for wet AMD: https://bit.ly/3Lhxwig

Innovative breakthroughs in the field of ophthalmology are definitely revolutionizing the treatment of the retinal diseases like macular degeneration, retinitis, pigmentosa and gyrate atrophy. https://lnkd.in/gKYEPzhQ

Exciting developments in ophthalmology! It's fascinating to see how companies are pushing boundaries to improve eye health. Check it out and share your thoughts! 👁️💡 #Ophthalmology #Innovation #HealthTech"

Ophthalmology is a growing area in clinical development, propelled by recent advancements and heightened attention to developing retinal disease solutions. Given the complexities in conducting ophthalmology trials, success often requires strong collaboration between the CRO and Sponsor. Medpace is a trusted ally, with deep experience in retinal diseases and strong team collaboration to help build long-term relationships with Sponsors. Dive deeper into the emerging trends of #ophthalmology in our latest blog from Zaiba Malik, M.D. and Tracy Huiet: https://lnkd.in/g857sdp4

Test your knowledge with a new HCPLive Clinician Quiz! In this quiz, we ask questions based on clinical assessment recommendations for patients with inherited retinal diseases from 2022 American Academy of Ophthalmology guidelines. https://lnkd.in/ew89WHrR #ophthalmology

Dealing with intermediate uveitis presents a challenge for ophthalmology trainees. I've tackled this by creating two educational videos on evaluation and management, which are published on the ONE network of the American Academy of Ophthalmology. In the first video, I focus on the evaluation of intermediate uveitis. Additionally, the video features a clear demonstration of the snowbanking sign—one often overlooked in the examination of many intermediate uveitis cases.The second part offers a practical approach, complete with a flowchart for efficient management. Access these resources through the links on the ONE network of the American Academy of Ophthalmology website. #uveitis  #uveitisfellow #ophthalmologists #ophthalmologyeducation#teaching https://lnkd.in/eVGMx9pT

In Retina Today, several leading experts in ophthalmology have shared their perspectives on nesvategrast (OTT166), our novel small molecule integrin inhibitor, as a promising candidate for the non-invasive treatment of diabetic retinopathy. Learn why Dr. Peter Kaiser views nesvategrast as a treatment that “would have tremendous impact as an easily used, patient-friendly option suitable for use in earlier stage disease.”: https://bit.ly/40VqaIa

“Current Practice and Future Options for Nonproliferative Diabetic Retinopathy,” recently published in Retina Today, highlights OcuTerra's novel small molecule selective integrin inhibitor, OTT166, updates on the Phase 2 DR:EAM clinical trial and some of the common myths about topical therapy and integrin inhibition. Read to learn more from top ophthalmology professionals like Dr. Jeffrey S. Heier, such as why he sees "potential for OTT166 to have an impact on slowing the progression to vision-threatening complications": https://bit.ly/40VqaIa

Ophthalmology Is Growing Strong One trend you can expect to see this year is growth. The ophthalmology therapeutics industry expects to expand substantially over the next several years. Unfortunately, one of the reasons for this growth is a high incidence of eye diseases, including glaucoma and macular degeneration. #ophthalmology #ophthalmic #medical #medicalequipmentsupplier